TELA Bio, Inc. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 68/100
What the filing says
TELA Bio appointed Heather Getz as CEO effective August 4, 2026. Q2 2026 revenue was $19.3M (down 4% vs. $20.2M in Q2 2025), driven by OviTex PRS volume declines and price/mix headwinds, partially offset by 26% international growth and 39% LiquiFix revenue growth. The company withdrew full-year 2026 guidance citing need to reassess strategy. Net loss widened to $11.3M in Q2 2026 vs. $9.9M in Q2 2025; cash decreased to $30.4M from $50.8M at year-end 2025; stockholders' equity swung to negative $15.9M from positive $6.3M.
Why this rating
Leadership change plus revenue decline, guidance withdrawal, and deteriorating balance sheet (negative equity) are material for a $76.8M company. Cash burn and leverage rising materially.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.